5 research outputs found
Adult intradural lipoma with tethered spinal cord syndrome
A 48-year-old woman presented to our imaging department with lumbar sciatica. The patient had a medical history of low back pain and spina bifida. A transverse section lumbar spine CT-scan, obtained with soft-tissue window setting (Fig. A, arrow) showed, a fat-density (45-HU), oblong, posterior intradural supracentimetric lesion, at level of L5-S1. The use of bone window setting revealed a spina bifida at L4-L5-S1 (Fig. B, arrow). Lumbar spine MRI performed shortly afterwards confirmed the presence of a posterior intradural supracentimetric lesion, at level of L5-S1, hyperintense on T1 (Fig. C, arrow) and T2, and hypointetense on T2 Stir weighted imaging (Fig. D, arrow), and showed that the filum terminale was attached to the aforementioned lesion. It also demonstrated that the conus medullaris was in an abdormally low position, set at the spinal level of L3-L4. Intradural spinal lipoma with tethered spinal cord was diagnosed. The patient will benefit from physiotherapy and a surgical option could be envisaged according to the clinical evolution
A complicated fourth branchial fistula
A 5-year-old girl was admitted to our Medical Imaging Departement for ultra - sonography of a painful and non-erythematous cervical mass on the left side of the neck. She previously complained of pain and dysphagia for several days. There is no fever and no history of infection
Scintigraphy and imaging of the oesophagus in children
peer reviewedThere are different type of abnormalities in the esophagus ranging from congential to acquired lesions. UGI series continue to be the most common radiologic method for evaluating esophagus
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
HER2DX is a prognostic and predictive assay in early-stage HER2-positive breast cancer based on clinical features and the expression of 4 gene signatures (immune, proliferation, luminal differentiation and HER2 amplicon), including ERBB2 mRNA levels. Here, we evaluated the ability of HER2DX to predict efficacy of a de-escalated, chemotherapy-free neoadjuvant regimen in HER2-positive/hormone receptor-positive breast cancer